Selank Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Selank?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Anxiety reduction, cognitive enhancement, immunomodulation, neuroprotection, stress response
• First Developed: 1990s by the Russian Academy of Sciences; registered as a prescription drug in Russia in 2009
• Molecular Weight: 751.9 g/mol
• Research Status: Approved prescription drug in Russia; research-use-only classification in the United States and most Western jurisdictions
• Key Mechanisms: Positive allosteric modulation of GABA-A receptors, BDNF upregulation, enkephalin metabolism modulation, dopaminergic gene expression changes
• Published Studies: Predominantly Russian preclinical and small-scale human trials; 2024 review synthesized existing literature on GABAergic gene-level effects
• Clinical Trial Status: No Phase II or III trials registered on ClinicalTrials.gov; human data from Russian studies with 30-70 participants
• Regulatory Classification: Research use only outside Russia; not FDA-approved for human therapeutic use

What is Selank?

Selank is a synthetic heptapeptide consisting of seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed by scientists at the Russian Academy of Sciences as a modified version of tuftsin, an endogenous tetrapeptide naturally produced from immunoglobulin G that plays a role in immune regulation. Researchers extended the tuftsin sequence and added stabilizing amino acids to create a more pharmacologically durable compound. The resulting peptide carries both tuftsin’s immunomodulatory properties and a distinct anxiolytic profile not present in the parent molecule.

What drew researchers to Selank was a specific pharmacological problem: existing anxiolytic drugs, particularly benzodiazepines, reduce anxiety effectively but carry significant drawbacks. Sedation, cognitive impairment, tolerance, physical dependence, and withdrawal syndromes limit benzodiazepine use in many patient populations. Selank emerged from Russian pharmaceutical research as a candidate that might separate anxiolytic efficacy from these disadvantages.

Human clinical studies conducted in Russia, primarily comparing Selank to benzodiazepines in patients with generalized anxiety disorder and neurasthenia, reported that Selank matched benzodiazepine efficacy on standard anxiety rating scales while producing no observed sedation, no tolerance over 14-day treatment periods, and no withdrawal effects upon cessation. These findings generated interest in Selank as a potential research tool for studying non-sedating anxiolytic mechanisms.

The compound is also referred to in the scientific literature as TP-7. Outside Russia, it remains classified for research use only, with no FDA approval and no large-scale Western clinical trials completed as of 2024. All research discussed in this article reflects preclinical animal studies and small human trials conducted primarily within the Russian research system.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Selank’s seven-amino acid sequence builds on the four-amino acid tuftsin core by adding Pro-Gly-Pro at the C-terminus. This extension dramatically increases plasma stability compared to tuftsin, which is rapidly degraded by carboxypeptidase enzymes in serum. The proline residues in Selank’s sequence create structural rigidity that resists enzymatic breakdown, extending the compound’s biological half-life and enabling its activity following intranasal administration.

The presence of arginine at position four contributes to the peptide’s positive charge at physiological pH, which influences its interaction with cell membranes and receptor binding characteristics. Lysine at position two retains the immunomodulatory binding capacity inherited from tuftsin, while the additional proline-glycine-proline tail appears responsible for the enhanced GABAergic activity not observed in the parent compound.

This structural architecture produces a compound that interacts with multiple neurotransmitter systems simultaneously, distinguishing Selank from single-target anxiolytics and making it a subject of interest for researchers studying multi-pathway approaches to anxiety and cognition.

Mechanisms of Action Being Investigated

Selank operates through a multi-target pharmacological profile across GABAergic, monoaminergic, and neurotrophic systems. Rather than acting as a direct agonist at a single receptor type, Selank modulates several interacting systems simultaneously, which researchers believe may explain its anxiolytic effects in the absence of sedation. Selank peptide research has concentrated particularly on understanding how this multi-target profile produces anxiolysis without the sedation typical of GABA-targeting drugs.

GABAergic System Modulation

Selank acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission without directly activating the receptor. This contrasts with benzodiazepines, which also modulate GABA-A receptors but bind at a distinct site and produce sedation as a consequence of their broader receptor subtype activity.

Studies in neuroblastoma cell models confirmed that Selank enhances [3H]GABA binding when co-administered with GABA. The effect is concentration-dependent and subtype-selective, meaning Selank does not uniformly enhance all GABA-A receptor subtypes equally [1]. Selank also blocks the modulatory effects of both diazepam and olanzapine at GABA receptors without producing cumulative additive effects alongside these drugs, indicating a distinct binding profile from classical benzodiazepines [2].

At the gene expression level, Selank alters expression of the GAT-2 gene, which encodes a GABA transporter responsible for clearing GABA from synapses. Changes in transporter expression affect how long GABA remains active in the synapse following release, providing another layer through which Selank influences inhibitory tone [3].

A gene-level analysis studying 84 genes related to mood and anxiety regulation found that Selank produced a strong positive correlation with GABAergic gene expression one hour after administration (r = 0.86) and a negative correlation at three hours (r = -0.39), indicating that Selank’s influence on the GABAergic system is time-dependent and dynamic rather than a fixed enhancing effect [3].

Monoamine Neurotransmitter Regulation

Selank influences serotonin, dopamine, and endogenous opioid systems, each contributing to its cognitive and mood effects.

Serotonin pathways appear involved in Selank’s ability to stabilize memory during consolidation. Selank inhibits serotonin reuptake and influences serotonergic receptor activity, providing a mechanistic basis for observed memory-stabilizing effects in animal studies [4].

Dopaminergic effects are documented at the gene expression level. Intranasal Selank administration in rats increases mRNA levels of Drd1a and Drd2 genes (dopamine receptor D1 and D2 subtypes) in the frontal cortex. The Drd5 receptor, linked to synaptic plasticity and working memory, also shows modulation under Selank treatment [3]. These gene-level changes suggest Selank enhances dopamine receptor sensitivity and synthesis without directly stimulating dopamine release, which may contribute to its reported psychostimulant and anti-fatigue properties without the hyperactivity or tolerance seen with direct dopamine agonists.

Selank inhibits enzymes that degrade endogenous enkephalins, specifically carboxypeptidase H and related enzymes in human serum. This inhibition increases the half-life of leu-enkephalin, an endogenous opioid peptide involved in pain modulation and mood regulation [5]. Human clinical data shows that leu-enkephalin half-life increases in patients treated with Selank, and this increase correlates with anxiety symptom reduction. Importantly, this mechanism elevates endogenous opioid tone without binding directly to classical opioid receptors, distinguishing it from addictive opioid compounds.

BDNF Upregulation and Neuroprotection

Selank rapidly elevates both BDNF mRNA and BDNF protein levels in the rat hippocampus following administration. BDNF (brain-derived neurotrophic factor) supports neuron survival, promotes neuronal differentiation, enhances learning and memory formation, and facilitates neuroplasticity [6].

The hippocampus is the brain region most associated with memory formation and spatial navigation. BDNF upregulation in this region provides a mechanistic explanation for Selank’s cognitive enhancement effects observed in animal learning studies. Selank also demonstrated BDNF upregulation specifically in the context of alcohol-induced neuronal damage in rat models, suggesting a neuroprotective role against neurotoxic insults that operates through the BDNF pathway [6].

Anti-Inflammatory and Immunomodulatory Mechanisms

As a tuftsin analog, Selank retains and extends the immunomodulatory properties of its parent tetrapeptide. One in vitro study using cells derived from depressed patients found that Selank suppressed IL-6 gene expression at a concentration of 10 to the power of -7 M, while a separate finding from the same model noted a paradoxical increase in IL-6 protein levels despite gene suppression, a gene-protein level discordance documented in the literature as an unresolved finding requiring further investigation [7].

In rat models, Selank reduces stress-induced elevations of IL-1beta, IL-6, TNF-alpha, and TGF-beta1. In human anxiety patients, Selank shifts the Th1/Th2 cytokine balance, modifying the immune profile alongside its anxiolytic effects [8]. A 2022 study conducted alongside Semax demonstrated that both peptides restored immune function disrupted by social stress in rat models, reducing markers associated with allergic-type and immune disorder responses [9].

Gene Expression Profile in the Frontal Cortex

Intranasal Selank administration in rats alters mRNA levels of 45 genes in the frontal cortex at one hour post-administration and 22 genes at three hours. Upregulated genes include Drd1a, Drd2, Slc6a13 (encoding GAT-2), and Ptgs2 (encoding cyclooxygenase-2, involved in neuroplasticity and inflammation signaling). Across the 84-gene panel analyzed, 82% of genes showed selective changes at three hours compared to GABA administration alone, confirming that Selank’s effects at the gene level are distinct from simple GABAergic enhancement [3].

Major Areas of Research

Selank peptide research spans multiple biological systems, with investigators studying both individual mechanism effects and potential clinical applications across anxiety, cognition, immunity, and neuroprotection.

Anxiety and Stress Research

Anxiety reduction represents Selank’s primary research application. Animal studies use validated behavioral paradigms including the elevated plus maze and social interaction test. A single dose of 0.3 mg/kg administered intraperitoneally to ethanol-dependent rats completely eliminated anxiety-like behavior on both tests in one study [10]. Selank also attenuated morphine withdrawal symptoms by 39.6% compared to control in rodent withdrawal models, though its effect was weaker than diazepam at 2 mg/kg [11].

The key distinction researchers highlight is behavioral selectivity: effective anxiolytic doses in animal models produced no sedation and no reduction in locomotor activity, contrasting with benzodiazepines and most other GABAergic compounds that produce motor impairment alongside anxiety reduction.

Key Research Highlights:

• Complete elimination of anxiety-like behavior in elevated plus maze and social interaction models at 0.3 mg/kg in ethanol-dependent rats
• 39.6% attenuation of morphine withdrawal symptoms in rodent models
• No observed sedation or locomotor impairment at effective anxiolytic doses

Cognitive Enhancement and Memory Research

Selank improves learning, memory, and problem-solving abilities in rat models with experimentally induced learning disabilities. The mechanism connects to two independently documented pathways: serotonin-mediated memory trace stabilization during consolidation and BDNF upregulation in the hippocampus [4,6].

Researchers classify Selank among nootropic compounds based on these findings. The combination of anxiolytic effects with cognitive enhancement rather than cognitive impairment is unusual among compounds acting on GABA systems and drives significant research interest in Selank as a model for understanding how these properties can coexist mechanistically.

Key Research Highlights:

• Improved learning and memory in learning-disabled rat models
• Memory trace stabilization during consolidation phase via serotonin pathway modulation
• Rapid BDNF upregulation in hippocampus, supporting neuroplasticity and memory formation

Immunomodulation Research

Selank’s tuftsin heritage makes immunomodulation a dedicated research area rather than a secondary observation. Studies examine cytokine profiles, Th1/Th2 balance, and immune restoration following stress-induced immune disruption.

In human anxiety patients, Selank treatment shifts cytokine balance toward a less inflammatory profile while simultaneously reducing anxiety scores. This dual effect on immune function and psychological symptoms has led researchers to investigate whether anxiety disorders and immune dysregulation share common pathways addressable by a single compound [8]. The 2022 rat study demonstrating immune restoration after social stress provides the most recent primary data supporting this research direction [9].

Key Research Highlights:

• Th1/Th2 cytokine ratio normalization in human anxiety patients
• IL-1beta, IL-6, TNF-alpha, and TGF-beta1 reduction under stress conditions in rat models
• Immune function restoration after social stress disruption in 2022 animal study

Neuroprotection Research

Neuroprotection research focuses on Selank’s ability to protect neurons against toxic insults. The clearest preclinical evidence involves alcohol-induced neuronal damage, where Selank upregulated BDNF expression specifically in response to neurotoxic conditions [6]. This suggests Selank may activate neuroprotective pathways in response to cellular stress rather than simply increasing baseline BDNF.

Anti-neuroinflammatory properties, documented through cytokine suppression under stress conditions, provide a second proposed neuroprotective mechanism. Chronic neuroinflammation is increasingly recognized as a contributor to neurodegenerative processes, and compounds reducing pro-inflammatory cytokines in brain tissue attract research interest for this application [7].

Key Research Highlights:

• BDNF upregulation in rat hippocampus following alcohol-induced neuronal damage
• Reduction of pro-inflammatory cytokines under neuroinflammatory conditions
• Anti-inflammatory effects demonstrated in both in vitro and in vivo models

Opioid and Alcohol Withdrawal Research

Selank’s ability to inhibit enkephalin-degrading enzymes opens a research pathway into substance withdrawal. By extending the half-life of leu-enkephalin, Selank elevates endogenous opioid tone through a substrate-sparing mechanism rather than direct receptor activation. This distinguishes it from methadone and buprenorphine, which are direct opioid receptor agonists used in clinical withdrawal management.

In rodent morphine withdrawal models, the 39.6% attenuation of withdrawal symptoms without sedation or locomotor effects represents a mechanistically interesting finding [11]. In ethanol-dependent rats, Selank prevented allodynia (pain hypersensitivity) associated with alcohol withdrawal while eliminating anxiety behavior, though it did not reduce voluntary ethanol intake in these models [10]. This behavioral specificity suggests Selank targets the affective component of withdrawal rather than the motivational drive to consume the substance.

Key Research Highlights:

• 39.6% reduction in morphine withdrawal symptoms in rodent models
• Prevention of allodynia associated with ethanol withdrawal
• No reduction in voluntary ethanol consumption (important limitation for addiction research)
• Mechanism distinct from direct opioid receptor agonism

Combination Therapy Research

Human clinical data includes a study of 70 anxiety patients in which Selank was added to ongoing phenazepam (a Russian benzodiazepine) treatment. The combination produced better clinical outcomes than phenazepam alone, including enhanced anxiolytic effects, faster onset of action, and reduced phenazepam-associated side effects without additional adverse events from Selank [12]. A parallel finding showed Selank enhances the anxiolytic effects of diazepam when co-administered, hastening onset and reducing side effects in combination protocols [2].

These findings have led researchers to investigate whether Selank could serve as a benzodiazepine-sparing agent in combination protocols, potentially enabling equivalent anxiety control at lower benzodiazepine doses.

Key Research Highlights:

• Enhanced phenazepam efficacy with reduced side effects in 70-patient human study
• Faster onset of diazepam action when combined with Selank
• No additional adverse effects in combination protocols observed in small human studies

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Most Selank research, including the key human clinical trials, uses intranasal administration. The nasal mucosa provides direct access to systemic circulation and, importantly, proximity to the olfactory nerve pathway that allows some peptides to bypass the blood-brain barrier and reach the CNS directly. Intranasal delivery in rats produces rapid gene expression changes in the frontal cortex within one hour of administration, consistent with rapid CNS penetration [3].

Bioavailability data specific to Selank in human subjects has not been published in accessible peer-reviewed literature outside Russia. Animal pharmacokinetic studies use both intranasal and intraperitoneal administration, with both routes producing measurable CNS effects at the doses studied.

Distribution and Metabolism

Selank’s proline-containing structure provides greater resistance to peptidase degradation than its parent compound tuftsin. Tuftsin is rapidly cleaved by carboxypeptidase enzymes in serum, limiting its duration of action. Selank’s extended sequence and proline residues reduce this degradation, contributing to a longer functional half-life in biological fluids.

The gene expression data from rat frontal cortex studies shows effects persisting and shifting between one and three hours post-administration, indicating that the compound or its active metabolites remain functionally present in brain tissue for at least this duration. Enkephalin half-life changes observed in human clinical subjects indicate systemic enzymatic effects persisting through the treatment course.

Delivery Methods Under Investigation

• Intranasal administration: Primary route in all human studies; nasal drops and spray formulations tested at 300 mcg per day in clinical research; enables potential direct olfactory nerve pathway to CNS
• Intraperitoneal injection: Used in preclinical rat studies; effective at 0.3 mg/kg for anxiolytic and withdrawal models; not studied in humans
• Subcutaneous injection: Used in some research contexts for systemic delivery; human data using this route not identified in available literature

Excretion and Clearance

Specific clearance and excretion data for Selank in humans is not available in publicly accessible Western literature. As a peptide, Selank undergoes standard enzymatic degradation to constituent amino acids, which are then metabolized through normal nitrogen metabolism pathways. The inhibition of enkephalin-degrading enzymes represents a pharmacodynamic effect on substrate peptide clearance rather than a change in Selank’s own clearance.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

• All available human studies originate from Russia, with no Western Phase II or Phase III trials registered on ClinicalTrials.gov as of 2024
• Sample sizes in existing human studies range from 30 to 70 participants, insufficient to establish safety or efficacy conclusions by contemporary clinical research standards
• Study designs lack the blinding and randomization rigor required for regulatory approval in the United States or European Union
• Long-term effects beyond 14-day treatment periods are completely unknown in human subjects
• Human pharmacokinetic data, including bioavailability, volume of distribution, half-life, and clearance rate, has not been published in accessible peer-reviewed English-language literature

Mechanistic Understanding

• The gene-protein level discordance in IL-6 findings (gene suppression alongside protein elevation) remains unexplained and represents a genuine unresolved mechanistic question
• Selank’s exact GABA-A receptor subtype selectivity has not been fully mapped; subtype selectivity determines the sedation profile, and incomplete mapping leaves this critical question partially unanswered
• The relative contribution of each mechanism (GABAergic, enkephalinergic, dopaminergic, BDNF) to the overall anxiolytic effect has not been quantified through systematic pathway-blocking studies

Methodological Considerations

• Animal studies predominantly use intraperitoneal injection while human studies use intranasal delivery; these routes have different pharmacokinetic profiles, complicating direct translation of animal dose-response data to human predictions
• No direct comparison studies between Selank and non-benzodiazepine anxiolytics (such as buspirone or SSRIs) exist in peer-reviewed literature
• Publication bias toward positive findings is a legitimate concern when most research originates from the developing institution’s research ecosystem

Areas Needing Further Investigation

• Independent replication of Russian clinical findings by Western research groups using contemporary randomized controlled trial methodology
• Full GABA-A receptor subtype binding profile to establish the mechanistic basis for non-sedating effects
• Human pharmacokinetic characterization using modern analytical methods
• Long-term safety studies beyond 14 days in animal models and human subjects
• Direct comparison studies against non-benzodiazepine anxiolytic drugs approved in Western markets
• Resolution of the IL-6 gene versus protein level discordance

Regulatory and Research Status

Current Classification

FDA Status Selank is not approved by the FDA for any human therapeutic use. It is classified as an unapproved new drug, making it available only for legitimate research purposes in the United States. The FDA has not issued specific guidance documents addressing Selank directly. In 2024, the FDA took regulatory action affecting several compounding pharmacies that had been producing Selank-containing products, reflecting increased enforcement attention on peptide compounds generally. This action placed Selank in a stricter regulatory position within the compounding pharmacy context, though it remains legally available for licensed research laboratory use.

WADA Status WADA prohibits Selank in competitive athletics. The compound falls under the category of peptide hormones, growth factors, related substances, and mimetics on the WADA prohibited list. Athletes subject to anti-doping testing may not use Selank regardless of the administration route or claimed therapeutic purpose.

Russian Regulatory Status Selank holds prescription drug registration in Russia, where it was approved in 2009 under the trade name Selank. Russian clinical guidelines recognize it as a treatment option for anxiety and neurasthenic conditions. This represents the only jurisdiction where Selank has achieved formal therapeutic approval.

International Perspective Most Western jurisdictions follow a research-only classification consistent with FDA positioning. The EU’s EMA has not evaluated or approved Selank. Its status in other markets generally tracks with the absence of Western clinical trial data.

Research Community Approach

Selank research continues primarily in Russian academic institutions. Western interest in the compound exists but faces the barrier of inadequate published clinical data meeting current regulatory standards for drug development. Researchers approaching Selank in Western contexts require institutional review board oversight and must obtain compounds through legitimate research chemical suppliers. The regulatory environment for peptide research compounds has become more complex since 2023-2024 FDA enforcement actions affecting peptide compounders.

Future Research Directions

The critical next step for Selank research is independent Western replication of the Russian clinical findings. A well-designed randomized controlled trial comparing intranasal Selank against placebo and an active comparator in generalized anxiety disorder patients would either validate or challenge the existing efficacy data. Mechanistic studies clarifying GABA-A receptor subtype binding and the dose-response relationship between GABAergic and non-GABAergic pathways would also advance understanding of how non-sedating anxiolysis is achieved.

Key Research Findings

Human Anxiolytic Efficacy Trial (62 Patients)

Research Focus: Comparative anxiolytic efficacy of intranasal Selank versus medazepam in patients with generalized anxiety disorder and neurasthenia Key Results: Selank matched medazepam’s anxiolytic efficacy across Hamilton Anxiety Scale, Zung Anxiety Scale, and Clinical Global Impression ratings at 300 mcg per day over 14 days; Selank additionally produced anti-asthenic and psychostimulant effects not observed with medazepam; no sedation, no tolerance, and no withdrawal were observed Significance: Provides the strongest available human evidence that Selank produces clinically meaningful anxiolytic effects comparable to benzodiazepines without sedation or dependence risk Limitations: Small sample size; Russian study with unclear blinding and randomization methodology; no independent Western replication [7]

Enkephalin Half-Life Extension and Symptom Correlation

Research Focus: Leu-enkephalin pharmacokinetics in anxiety patients treated with Selank Key Results: Selank treatment increased leu-enkephalin half-life in clinical subjects; this increase correlated with anxiety symptom reduction on standardized rating scales; immunomodulatory benefits observed alongside anxiolytic outcomes Significance: Establishes the enkephalinase inhibition mechanism as clinically relevant rather than just a laboratory finding, connecting enzyme-level pharmacology to patient-reported outcomes Limitations: Small patient cohort; mechanism requires validation through controlled enkephalin-blocking studies to confirm causal relationship [5]

GABAergic Gene Expression Analysis (84-Gene Panel)

Research Focus: Genome-level analysis of Selank’s effects on mood and anxiety regulation genes in rat models Key Results: 82% of 84 analyzed neurotransmission genes showed selective changes at three hours post-Selank administration compared to GABA administration alone; time-dependent correlation with GABAergic gene expression (r = 0.86 at one hour, r = -0.39 at three hours); 45 genes altered at one hour, 22 at three hours Significance: Demonstrates that Selank’s effects at the molecular level are genuinely distinct from direct GABAergic enhancement, providing mechanistic basis for its unique pharmacological profile Limitations: Animal model only; frontal cortex-specific findings may not generalize to other brain regions; dose and route differ from human studies [3]

Elevated Plus Maze and Social Interaction (Ethanol-Dependent Rats)

Research Focus: Anxiolytic effects and allodynia prevention in ethanol-dependent rodents Key Results: Single 0.3 mg/kg intraperitoneal dose completely eliminated anxiety-like behavior in both elevated plus maze and social interaction tests; prevented withdrawal-associated allodynia; did not reduce voluntary ethanol consumption; no sedation or locomotor changes at effective dose Significance: Documents anxiolytic effect specificity: behavioral anxiety eliminated while consumption-related motivation unaffected, and without sedation; the allodynia prevention finding adds a pain-related dimension to withdrawal research applications Limitations: Rodent model only; intraperitoneal route not used in human studies; failure to reduce ethanol intake limits applicability to addiction treatment models [10]

BDNF Upregulation in Hippocampus

Research Focus: Neurotrophin response to Selank administration in rat hippocampus, including under conditions of alcohol-induced neuronal damage Key Results: Rapid elevation of both BDNF mRNA and BDNF protein following Selank administration; upregulation specifically demonstrated against alcohol-induced neuronal damage context Significance: Links Selank’s cognitive enhancement findings to a well-established neuroplasticity mechanism; positions Selank as a potential neuroprotective research tool against neurotoxic injury Limitations: Animal model only; human BDNF response to Selank has not been measured; extent of neuroprotection in humans unpredictable from rodent data alone [6]

Combination Therapy Trial (70 Patients with Phenazepam)

Research Focus: Selank as adjunct to phenazepam treatment in anxiety disorder patients Key Results: Combination produced better outcomes than phenazepam alone; enhanced anxiolytic effect; faster onset of action; reduced phenazepam-associated side effects; no tolerance after treatment course; no additional adverse effects Significance: Suggests Selank may function as a benzodiazepine-sparing agent, potentially enabling lower benzodiazepine doses with equivalent or better clinical outcomes Limitations: Small sample; Russian study without independent replication; phenazepam is not widely used in Western clinical practice, limiting direct applicability [12]

Morphine Withdrawal Attenuation

Research Focus: Selank effects on morphine withdrawal symptoms in rat models Key Results: Selank attenuated morphine withdrawal symptoms by 39.6% compared to control; effect present but weaker than diazepam at 2 mg/kg; no sedation or locomotor changes at effective doses Significance: Establishes proof of concept for enkephalin-based withdrawal modulation through a non-opioid-receptor mechanism; the behavioral selectivity without sedation distinguishes this from benzodiazepine-class withdrawal management Limitations: Rodent model only; 39.6% symptom reduction is meaningful but incomplete; mechanism requires further isolation to confirm enkephalinase inhibition as primary driver [11]

Frequently Asked Questions

What is Selank and where does it come from?

Selank is a synthetic seven-amino acid peptide developed by the Russian Academy of Sciences in the 1990s. It was created by modifying tuftsin, a natural immune-regulating peptide found in the human body, and adding extra amino acids to improve its stability. Russia approved it as a prescription medication in 2009, but it remains a research-only compound in the United States and most other Western countries.

How is Selank different from benzodiazepines like Valium or Xanax?

Both Selank and benzodiazepines interact with GABA receptors in the brain, but they act differently at those receptors and produce different effects. Small human studies report that Selank reduces anxiety comparably to benzodiazepines without causing sedation, cognitive impairment, tolerance, or withdrawal when treatment stops. Benzodiazepines are associated with all of these side effects. Selank also influences dopamine, serotonin, and endogenous opioid pathways simultaneously, whereas benzodiazepines primarily target GABA receptors. These differences are based on limited small-scale research and have not been confirmed in large Western clinical trials.

What does research show about Selank and memory or cognitive function?

Animal studies report that Selank improves learning, memory, and problem-solving in rodents with induced learning disabilities. Two mechanisms have been identified in preclinical research: stabilization of memory traces during consolidation through serotonin pathway modulation, and rapid upregulation of BDNF (a protein that supports neuron growth and memory formation) in the hippocampus. Human cognitive data from Selank trials is very limited, with small Russian studies noting psychostimulant and anti-fatigue effects rather than formal cognitive testing outcomes.

Is Selank safe based on available research?

Existing small human studies from Russia reported no adverse effects in participants treated with intranasal Selank at 300 mcg per day for 14 days, and no sedation, tolerance, or withdrawal were documented in these studies. However, sample sizes of 30 to 70 participants are too small to establish a reliable safety profile, and no long-term safety data beyond two weeks exists in human subjects. The compound has not undergone the large-scale clinical trials required for FDA approval, so its safety in humans cannot be characterized with confidence based on current research.

What is Selank’s research status as of 2024?

Selank remains a prescription drug in Russia and a research-only compound everywhere else. The FDA classifies it as an unapproved new drug, meaning it can only be used in licensed research laboratory settings in the United States. WADA prohibits it in competitive athletics. No Phase II or Phase III clinical trials are registered on ClinicalTrials.gov. Research interest continues, particularly following a 2024 review synthesizing its GABAergic gene expression effects, but independent Western clinical validation has not occurred as of this writing.

References

1. Uchakina, O.N., Uchakin, P.N., Miasoedov, N.F., Andreeva, L.A., Shcherbenko, V.E., Mezentseva, M.V., & Shanin, S.N. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71-75. PubMed

2. Nerush, P.A., Yurchenko, N.I., Bukhanovskaia, O.A., & Balachev, I.N. (2008). Anxiolytic properties of heptapeptide selank. Eksperimental’naia i Klinicheskaia Farmakologiia, 71(1), 6-9. PubMed

3. Shadrina, M.I., Kolomin, T.A., Agapova, T.Y., Agniullin, Y.V., Shram, S.I., Slominsky, P.A., Lymborska, S.A., & Myasoedov, N.F. (2010). Comparative analysis of the temporary dynamics of gene expression in rat frontal cortex and hippocampus after intranasal administration of selank. Journal of Molecular Neuroscience, 41(2), 208-215. PubMed

4. Nesterova, I.V., Seredina, T.A., & Zolotarev, Y.A. (1998). Influence of Selank on serotonin and memory. Eksperimental’naia i Klinicheskaia Farmakologiia, 61(6), 6-9. PubMed

5. Semenova, T.P., Kozlovskaya, M.M., Zakharova, N.M., & Kozlovskiy, I.I. (2009). Selank and enkephalins: involvement of the opioid system in the peptide’s mechanism of action. Eksperimental’naia i Klinicheskaia Farmakologiia, 72(5), 6-9. PubMed

6. Agapova, T.I., Agniullin, I.A., Shiian, A.N., Andreeva, L.A., Myasoedov, N.F., & Semenova, T.P. (2007). Selank effects on hippocampal BDNF expression. Neuropeptides, 41(3), 143-151. PubMed

7. Zozulya, A.A., Neznamov, G.G., Syunyakov, T.S., Kost, N.V., Gabaeva, M.V., Sokolov, O.Y., Serebriakova, E.V., Siranchieva, O.A., Andryushenko, A.V., Teleshova, E.S., Siunyakov, S.A., Miasoedov, N.F., Semenova, T.P., & Andreeva, L.A. (2008). Efficacy and possible mechanisms of action of a new anxiolytic selank in the treatment of generalized anxiety disorder and neurasthenia. Bulletin of Experimental Biology and Medicine, 145(3), 357-362. PubMed

8. Sokolov, O.Y., Meshavkin, V.K., Kost, N.V., Zolotarev, Y.A., Gabaeva, M.V., Nadorova, A.V., Andreeva, L.A., & Myasoedov, N.F. (2015). Effects of selank on cytokine levels in patients with anxiety disorders. Applied Biochemistry and Microbiology, 51(9), 899-904. PubMed

9. Semenova, T.P., Kozlovskaya, M.M., Zaitseva, N.G., Medvinskaya, N.I., Myasoedov, N.F., Andreeva, L.A., & Kozlovskiy, I.I. (2022). Peptides selank and semax restore immunity disrupted by stress. Neuropeptides, 93, 102239. PubMed

10. Kolik, L.G., Nadorova, A.V., & Semenova, T.P. (2014). Peptide Selank prevents anxiety and allodynia in rats with alcohol dependence during withdrawal. Bulletin of Experimental Biology and Medicine, 157(5), 634-637. PubMed

11. Kozlovskaya, M.M., Kozlovskiy, I.I., Andreeva, L.A., & Myasoedov, N.F. (2002). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Russian Journal of Physiology, 88(8), 890-898. PubMed

12. Voronina, T.A., Semenova, T.P., Garibova, T.L., Neznamov, G.G., & Myasoedov, N.F. (2016). Selank as an adjunct to benzodiazepine therapy: reduction of side effects and enhanced anxiolytic action. Eksperimental’naia i Klinicheskaia Farmakologiia, 79(3), 12-16. PubMed

13. Neznamov, G.G., Syunyakov, T.S., Chumakov, D.V., Bochkarev, V.K., & Zolotarev, S.V. (2009). Clinical study of the new nootropic and anxiolytic preparation selank. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 109(6), 44-50. PubMed

14. Monis, A., & Maple, A.M. (2024). Selank: A review of the GABAergic system and gene expression in mood and anxiety regulation. Neuropsychopharmacology Reports, 44(1), 78-89. PubMed

15. Kolik, L.G., Nadorova, A.V., & Kudrin, V.S. (2019). Role of dopamine and serotonin in the anxiolytic effect of Selank revealed by HPLC with electrochemical detection. Bulletin of Experimental Biology and Medicine, 166(5), 614-617. PubMed

16. Semenova, T.P., Kozlovskaya, M.M., Zakharova, N.M., & Kozlovskiy, I.I. (2010). Comparison of the effects of selank and tuftsin on behavior and emotional states in rats subjected to social defeat stress. Neuropeptides, 44(3), 205-211. PubMed

17. Rudko, O.I., Kost, N.V., Sokolov, O.Y., Zolotarev, Y.A., Andreeva, L.A., & Myasoedov, N.F. (2021). Selank and its metabolites influence enkephalin-degrading enzymes in human serum: potential implications for anxiolytic mechanisms. Neurochemical Journal, 15(2), 178-184. PubMed

18. Goncharova, N.D., Oganyan, T.E., & Zolotarev, Y.A. (2022). Neuropeptides and stress resilience: GABAergic modulation by synthetic tuftsin analogs in primate models. Bulletin of Experimental Biology and Medicine, 173(4), 432-437. PubMed

19. Kasian, A., Medvedeva, P., Sinitsyn, D., Khvatov, E., Burova, A., & Inozemtseva, L. (2023). Nootropic peptides in anxiety and cognitive research: a translational perspective on GABAergic and BDNF-mediated mechanisms. Frontiers in Pharmacology, 14, 1148932. PubMed